Literature DB >> 33583064

Preserved eye movements in adults with spinal muscular atrophy.

Evangelos Anagnostou1, Sophia Xirou1, Evangelia Kararizou1, Leonidas Stefanis1, Constantinos Papadopoulos1, George Papadimas1.   

Abstract

INTRODUCTION: Spinal muscular atrophy (SMA) most prominently affects proximal limb and bulbar muscles. Despite older case descriptions, ocular motor neuron palsies or other oculomotor abnormalities are not considered part of the phenotype.
METHODS: We investigated oculomotor function by testing saccadic eye movements of 15 patients with SMA. Their performance was compared with that of age-matched healthy controls. Horizontal rightward and leftward saccades were recorded by means of video-oculography, whereas subjects looked at light-emitting diode targets placed at ±5°, ±10°, and ±15° eccentricities.
RESULTS: No differences in saccade amplitude gains, peak velocities, peak velocity-to-amplitude ratios, or durations were observed between controls and patients. More specifically, for 5° target eccentricities, patients had a mean saccadic peak velocity of 153°/s, whereas for 10° and 15° these values were 268°/s and 298°/s, respectively. The corresponding mean peak velocities of the control group were 151°/s, 264°/s, and 291°/s. DISCUSSION: Our results indicate that patients with SMA perform fast and accurate horizontal saccades without evidence of extraocular muscle weakness. These quantitative oculomotor data corroborate clinical experience that neuro-ophthalmic symptoms in SMA are not common and, if present, should prompt suspicion for an alternative neuromuscular disorder.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  extraocular muscles; eye movements; neuro-ophthalmology; saccades; spinal muscular atrophy

Year:  2021        PMID: 33583064     DOI: 10.1002/mus.27204

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  1 in total

1.  Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen.

Authors:  Yukako Yae; Kotaro Yuge; Toshiyuki Maeda; Fumio Ichinose; Muneaki Matsuo; Osamu Kobayashi; Kazuo Okanari; Yusei Baba; Chihiro Yonee; Shinsuke Maruyama; Minoru Shibata; Tatsuya Fujii; Madoka Chinen; Yushiro Yamashita
Journal:  Front Neurol       Date:  2022-09-30       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.